Predictive value of the phosphorylation of signal transducers and activators of transcription in the outcome of interferon therapy for chronic hepatitis C

Intervirology

Volumn 51, Issue 6, 2009, Pages 394-399

  Miyaaki, Hisamitsu ^a   Ichikawa, Tatsuki ^a   Nakao, Kazuhiko ^a   Takeshita, Shigeyuki ^a   Shibata, Hidetaka ^a   Ozawa, Eisuke ^a   Akiyama, Motohisa ^a   Miuma, Satoshi ^a   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatitis C virus; Insulin resistance; Interferon; Liver; STAT

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN; STAT1 PROTEIN; STAT3 PROTEIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA VIRUS; THERAPY RESISTANCE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER; MALE; MIDDLE AGED; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 61349194476     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000205264     Document Type: Article

References (26)

1. Mangia A, Ricci GL, Persico M, Minerva N, Carretta V, Bacca D, Cela M, Piattelli M, Annese M, Maio G, Conte D, Guadagnino V, Pazienza V, Festi D, Spirito F, Andriulli A: A randomized controlled trial of pegylated interferon- 2 a (40 kDa) or interferon- 2 a plus ribavirin and amantadine vs. interferon- 2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepat 2005; 12: 292-299.
2. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Kumada H: Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-410.
3. Wedemeyer H, Wiegand J, Cornberg M: Polyethylene glycol-interferon: current status in hepatitis C virus therapy. J Gastroenterol Hepatol 2002; 17(suppl 3):S344-S350.
4. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J: Interferon- 2 b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-1499.
5. Poynard T, Marcellin P, Bissery A, Myers RP, Moussalli J, Degos F, Dhumeaux D, Riachi G, Bronowicki JP, Brissot P, Buffet C, Serfaty L, Naveau S, Sogni P, Beaugrand M, Gayno S, Larrey D, Samuel D, Eugene C, Pol S, Bedossa P, Daurat V, Chaumet-Riffaud P: Reinforced interferon- 2 b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial. J Viral Hepat 2003; 10: 197- 204.
6. Pawlotsky JM, Germanidis G, Neumann AU, Pellerin M, Frainais PO, Dhumeaux D: Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations. J Virol 1998; 72: 2795-2805.
7. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C: Comparison of fulllength sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-230.
8. Puig-Basagoiti F, Forns X, Furcic I, Ampurdanes S, Gimenez-Barcons M, Franco S, Sanchez- Tapias JM, Saiz JC: Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. J Gen Virol 2005; 86: 1067-1075.
9. Ihle JN: The Stat family in cytokine signaling. Curr Opin Cell Biol 2001; 13: 211-217.
10. Heim MH: Intracellular signalling and antiviral effects of interferons. Dig Liver Dis 2000; 32: 257-263.
11. Yang CH, Murti A, Pfeffer LM: STAT3 complements defects in an interferon-resistant cell line: evidence for an essential role for STAT3 in interferon signaling and biological activities. Proc Natl Acad Sci USA 1998; 95: 5568-5572.
12. Zhu H, Shang X, Terada N, Liu C: STAT3 induces anti-hepatitis C viral activity in liver cells. Biochem Biophys Res Commun 2004; 324: 518-528.
13. Platanias LC: Mechanisms of type I and type II interferon-mediated signalling. Nat Rev Immunol 2005; 5: 375-386.
14. Konishi I, Horiike N, Hiasa Y, Tokumoto Y, Mashiba T, Michitaka K, Miyake Y, Nonaka S, Joukou K, Matsuura B, Onji M: Diabetes mellitus reduces the therapeutic effectiveness of interferon- 2 b plus ribavirin therapy in patients with chronic hepatitis C. Hepatol Res 2007; 37: 331-336.
15. Sanyal AJ, Chand N, Comar K: Hyperinsulinemia blocks the inhibition of HCV replication by interferon: a potential mechanism for failure of interferon therapy in subjects with HCV and NASH. Hepatology 2004; 40: 179A.
16. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE: Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529-535.
17. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J: Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 1695- 1704.
18. Muzzi A, Leandro G, Rubbia-Brandt L, James R, Keiser O, Malinverni R, Dufour JF, Helbling B, Hadengue A, Gonvers JJ, Mullhaupt B, Cerny A, Mondelli MU, Negro F: Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005; 42: 41-46.
19. Jacoby JJ, Kalinowski A, Liu MG, Zhang SS, Gao Q, Chai GX, Ji L, Iwamoto Y, Li E, Schneider M, Russell KS, Fu XY: Cardiomyocyte- restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA 2003; 100: 12929- 12934.
20. Williams L, Bradley L, Smith A, Foxwell B: Signal transducer and activator of transcription 3 is the dominant mediator of the antiinflammatory effects of IL-10 in human macrophages. J Immunol 2004; 172: 567- 576.
21. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, Taub R: Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996; 274: 1379-1383.
22. Li W, Liang X, Kellendonk C, Poli V, Taub R: STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem 2002; 277: 28411-28417.
23. Luquin E, Larrea E, Civeira MP, Prieto J, Aldabe R: HCV structural proteins interfere with interferon- Jak/STAT signalling pathway. Antiviral Res 2007; 76: 194-197.
24. Lin W, Kim SS, Yeung E, Kamegaya Y, Blackard JT, Kim KA, Holtzman MJ, Chung RT: Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol 2006; 80: 9226- 9235.
25. Larrea E, Aldabe R, Molano E, Fernandez- Rodriguez CM, Ametzazurra A, Civeira MP, Prieto J: Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: in vivo and in vitro studies. Gut 2006; 55: 1188-1196.
26. Melen K, Fagerlund R, Nyqvist M, Keskinen P, Julkunen I: Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs. J Med Virol 2004; 73: 536-547.